Bayer’s €4bn CB works but investors are not carefree yet
Bayer successfully pulled off what was arguably this year’s biggest European ECM deal on Tuesday night, with a €4bn mandatory convertible and €1.5bn delta equity placement. But although both were fully sold and have traded stably, a good number of deal-playing investors are still putting in small orders.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: